MX2018012539A - Composiciones y métodos de células t receptoras de aloantígeno quimérico. - Google Patents
Composiciones y métodos de células t receptoras de aloantígeno quimérico.Info
- Publication number
- MX2018012539A MX2018012539A MX2018012539A MX2018012539A MX2018012539A MX 2018012539 A MX2018012539 A MX 2018012539A MX 2018012539 A MX2018012539 A MX 2018012539A MX 2018012539 A MX2018012539 A MX 2018012539A MX 2018012539 A MX2018012539 A MX 2018012539A
- Authority
- MX
- Mexico
- Prior art keywords
- callar
- compositions
- cells
- methods
- alloantigen receptor
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000000961 alloantigen Effects 0.000 title abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
La invención incluye composiciones que comprenden al menos un receptor de aloantígeno quimérico (CALLAR) específico para un aloanticuerpo, vectores que comprenden el mismo, composiciones que comprenden vectores de CALLAR empacados en partículas virales, y células T recombinantes que comprenden el CALLAR; la invención también incluye métodos para preparar una célula T genéticamente modificada que expresa un CALLAR, en donde el CALLAR expresado comprende un factor VIII o fragmento del mismo en el dominio extracelular.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662322937P | 2016-04-15 | 2016-04-15 | |
PCT/US2017/027754 WO2017181101A1 (en) | 2016-04-15 | 2017-04-14 | Compositions and methods of chimeric alloantigen receptor t cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018012539A true MX2018012539A (es) | 2019-07-08 |
Family
ID=60042268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012539A MX2018012539A (es) | 2016-04-15 | 2017-04-14 | Composiciones y métodos de células t receptoras de aloantígeno quimérico. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20190153064A1 (es) |
EP (1) | EP3443076A4 (es) |
JP (2) | JP2019513394A (es) |
KR (1) | KR20190003550A (es) |
CN (1) | CN109328230A (es) |
AU (2) | AU2017248817A1 (es) |
CA (1) | CA3020599A1 (es) |
MX (1) | MX2018012539A (es) |
RU (1) | RU2018140056A (es) |
WO (1) | WO2017181101A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210023170A1 (en) * | 2018-02-12 | 2021-01-28 | University Of Florida Research Foundation, Incorporated | Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a |
JP7386848B2 (ja) * | 2018-08-28 | 2023-11-27 | 法▲羅▼斯疫苗株式会社 | 改良されたレンチウイルスベクター |
KR20210063348A (ko) * | 2018-08-28 | 2021-06-01 | 이뮤노테크 바이오팜 씨오., 엘티디. | 개선된 치료용 t 세포 |
CN110903399B (zh) * | 2018-09-17 | 2022-02-01 | 台湾中国医药大学附设医院 | 嵌合抗原受体、其核酸、表达质体、细胞、用途及组合物 |
AU2020275776A1 (en) * | 2019-05-13 | 2021-12-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of acetylcholine receptor chimeric autoantibody receptor cells |
US20230270782A1 (en) * | 2020-09-03 | 2023-08-31 | Porton Advanced Solutions Ltd. | Compositions and methods to target anti-rh antibody |
CN114369168A (zh) * | 2020-10-19 | 2022-04-19 | 南京卡提医学科技有限公司 | 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法 |
WO2022083590A1 (zh) * | 2020-10-19 | 2022-04-28 | 南京卡提医学科技有限公司 | 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US466A (en) | 1837-11-20 | Jordan l | ||
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
ATE373078T1 (de) | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | Gleichzeitige stimulation und konzentration von zellen |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
EP2470561A1 (en) * | 2009-08-27 | 2012-07-04 | Novo Nordisk A/S | Targeting tissue factor to activated platelets |
EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
US20150290244A1 (en) * | 2012-07-13 | 2015-10-15 | The Trustees Of The University Of Pennsylvania | Use of cart19 to deplete normal b cells to induce tolerance |
WO2014160627A1 (en) * | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
WO2015168613A2 (en) * | 2014-05-02 | 2015-11-05 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
AU2015255979B2 (en) * | 2014-05-08 | 2019-11-21 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses |
WO2017095525A1 (en) * | 2015-12-04 | 2017-06-08 | David Scott | Antigen-specific t cells for inducing immune tolerance |
-
2017
- 2017-04-14 US US16/093,539 patent/US20190153064A1/en not_active Abandoned
- 2017-04-14 EP EP17783306.8A patent/EP3443076A4/en active Pending
- 2017-04-14 CA CA3020599A patent/CA3020599A1/en active Pending
- 2017-04-14 AU AU2017248817A patent/AU2017248817A1/en not_active Abandoned
- 2017-04-14 JP JP2018553980A patent/JP2019513394A/ja active Pending
- 2017-04-14 CN CN201780036162.2A patent/CN109328230A/zh active Pending
- 2017-04-14 RU RU2018140056A patent/RU2018140056A/ru unknown
- 2017-04-14 MX MX2018012539A patent/MX2018012539A/es unknown
- 2017-04-14 KR KR1020187032117A patent/KR20190003550A/ko not_active Application Discontinuation
- 2017-04-14 WO PCT/US2017/027754 patent/WO2017181101A1/en active Application Filing
-
2021
- 2021-08-23 US US17/409,354 patent/US20220220188A1/en active Pending
-
2022
- 2022-06-15 JP JP2022096329A patent/JP2022133308A/ja active Pending
-
2023
- 2023-09-01 AU AU2023222993A patent/AU2023222993A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2023222993A1 (en) | 2023-11-02 |
JP2022133308A (ja) | 2022-09-13 |
RU2018140056A3 (es) | 2020-10-16 |
JP2019513394A (ja) | 2019-05-30 |
EP3443076A1 (en) | 2019-02-20 |
KR20190003550A (ko) | 2019-01-09 |
WO2017181101A1 (en) | 2017-10-19 |
US20190153064A1 (en) | 2019-05-23 |
AU2017248817A1 (en) | 2018-11-15 |
CA3020599A1 (en) | 2017-10-19 |
EP3443076A4 (en) | 2020-04-15 |
US20220220188A1 (en) | 2022-07-14 |
RU2018140056A (ru) | 2020-05-15 |
CN109328230A (zh) | 2019-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018012539A (es) | Composiciones y métodos de células t receptoras de aloantígeno quimérico. | |
WO2015168613A3 (en) | Compositions and methods of chimeric autoantibody receptor t cells | |
PH12020552138A1 (en) | Bcma chimeric antigen receptors and uses thereof | |
AU2023200884B2 (en) | Human mesothelin chimeric antigen receptors and uses thereof | |
WO2017147383A8 (en) | Modified cells for immunotherapy | |
MX2022000132A (es) | Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. | |
IL278857A (en) | Recombinant nk cells expressing an fc-epsilon chimric antigen receptor (car) and uses thereof | |
IL277587A (en) | Expression vectors for chimeric phagocytic receptors, genetically modified host cells and uses thereof | |
MX2019001184A (es) | Anticuerpos anti-idiotípicos y métodos relacionados. | |
SG10201900455YA (en) | Bcma chimeric antigen receptors | |
IL284744A (en) | GPRC5D chimeric antigen receptors and cells expressing them | |
MX2017003640A (es) | Receptores antigenicos quimericos. | |
MX2022008013A (es) | Estabilizacion de polipeptidos que contienen fragmentos cristalizables. | |
MX2020001227A (es) | Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes. | |
MX2021007011A (es) | Receptores de antigenos quimericos de antigeno de maduracion de celulas b. | |
MX2020011610A (es) | Composiciones y métodos de células t receptoras de autoanticuerpo quimérico del receptor de fosfolipasa a2. | |
NZ735778A (en) | Kappa myeloma antigen chimeric antigen receptors and uses thereof | |
MX2015005675A (es) | Composiciones y metodos para modular la comunicacion celular. | |
MX2017002605A (es) | Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas. | |
WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
MX2018013738A (es) | Anticuerpos que comprenden dominios constantes quimericos. | |
WO2014008480A3 (en) | Cell line expressing single chain factor viii polypeptides and uses thereof | |
MX2015014568A (es) | Composiciones y metodos para tratar y prevenir la degeneracion macular. | |
EA201691548A1 (ru) | Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды | |
AU2016335217A8 (en) | Antigen receptors and uses thereof |